The University of Southampton
University of Southampton Institutional Repository

12-month efficacy and safety of OROS® MPH in children and adolescents with attention deficit/hyperactivity disorder switched from MPH

12-month efficacy and safety of OROS® MPH in children and adolescents with attention deficit/hyperactivity disorder switched from MPH
12-month efficacy and safety of OROS® MPH in children and adolescents with attention deficit/hyperactivity disorder switched from MPH
PURPOSE: The aim of this study was to evaluate long-term clinical treatment with OROS methylphenidate (MPH) (Concerta) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH.

METHODS: Subjects aged 6-16 years (n=105) who were stable on IR MPH (10-60 mg/day) were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators.

RESULTS: Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10-16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS MPH was well tolerated.

CONCLUSIONS: Children and adolescents can effectively and safely be switched from IR MPH to OROS MPH with improved symptom control and compliance.

1018-8827
305-309
Hoare, P.
bd0cbb54-8378-47fa-946e-6bf35a19bfc3
Remschmidt, H.
777abe28-b7fe-4dd5-b31d-31a1e38e6051
Medori, R.
2a565b97-0e25-4133-a25e-66d1f6f6df54
Ettrich, C.
c3f739e3-b273-4912-88ba-e05619d5b9ff
Rothenberger, A.
f946fbda-7ceb-46b0-b48d-23cdaa4016aa
Santosh, P.
83759ca4-e254-4733-be8d-df022df6ce89
Schmidt, M.
68f4851a-9b14-48a9-b08f-854618465310
Spender, Q.
d00dc50d-3116-40a9-8c9b-f9231e893d9d
Tamhne, R.
13a55c60-5f75-4ef7-96bc-43ed88fe95d6
Thompson, M.
bfe8522c-b252-4771-8036-744e93357c67
Tinline, C.
2aa195bb-e46e-4ee4-96d7-3b4d64597ab9
Trott, G.E.
538e7045-7fa7-45c7-bd87-59271ea29930
Hoare, P.
bd0cbb54-8378-47fa-946e-6bf35a19bfc3
Remschmidt, H.
777abe28-b7fe-4dd5-b31d-31a1e38e6051
Medori, R.
2a565b97-0e25-4133-a25e-66d1f6f6df54
Ettrich, C.
c3f739e3-b273-4912-88ba-e05619d5b9ff
Rothenberger, A.
f946fbda-7ceb-46b0-b48d-23cdaa4016aa
Santosh, P.
83759ca4-e254-4733-be8d-df022df6ce89
Schmidt, M.
68f4851a-9b14-48a9-b08f-854618465310
Spender, Q.
d00dc50d-3116-40a9-8c9b-f9231e893d9d
Tamhne, R.
13a55c60-5f75-4ef7-96bc-43ed88fe95d6
Thompson, M.
bfe8522c-b252-4771-8036-744e93357c67
Tinline, C.
2aa195bb-e46e-4ee4-96d7-3b4d64597ab9
Trott, G.E.
538e7045-7fa7-45c7-bd87-59271ea29930

Hoare, P., Remschmidt, H., Medori, R., Ettrich, C., Rothenberger, A., Santosh, P., Schmidt, M., Spender, Q., Tamhne, R., Thompson, M., Tinline, C. and Trott, G.E. (2005) 12-month efficacy and safety of OROS® MPH in children and adolescents with attention deficit/hyperactivity disorder switched from MPH. European Child & Adolescent Psychiatry, 14 (6), 305-309. (doi:10.1007/s00787-005-0486-3).

Record type: Article

Abstract

PURPOSE: The aim of this study was to evaluate long-term clinical treatment with OROS methylphenidate (MPH) (Concerta) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH.

METHODS: Subjects aged 6-16 years (n=105) who were stable on IR MPH (10-60 mg/day) were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators.

RESULTS: Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10-16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS MPH was well tolerated.

CONCLUSIONS: Children and adolescents can effectively and safely be switched from IR MPH to OROS MPH with improved symptom control and compliance.

Full text not available from this repository.

More information

Published date: September 2005

Identifiers

Local EPrints ID: 58929
URI: http://eprints.soton.ac.uk/id/eprint/58929
ISSN: 1018-8827
PURE UUID: 4997b655-e8f9-479d-8978-573b5d1eb01e

Catalogue record

Date deposited: 19 Aug 2008
Last modified: 13 Mar 2019 20:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×